IMPAX LABORATORIES INC 4
4 · IMPAX LABORATORIES INC · Filed Sep 1, 2015
Insider Transaction Report
Form 4
MARKBREITER MICHAEL
Director
Transactions
- Exercise/Conversion
Common Stock
2015-08-28$17.99/sh+8,000$143,920→ 16,200 total - Sale
Common Stock
2015-08-28$42.48/sh−8,000$339,840→ 8,200 total - Exercise/Conversion
Common Stock
2015-08-31$20.90/sh+10,000$209,000→ 18,200 total - Sale
Common Stock
2015-08-31$41.39/sh−10,000$413,900→ 8,200 total - Exercise/Conversion
Stock Option (Right to Buy)
2015-08-28−8,000→ 4,000 totalExercise: $17.99Exp: 2023-05-15→ Common Stock (8,000 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2015-08-31−10,000→ 0 totalExercise: $20.90Exp: 2022-05-23→ Common Stock (10,000 underlying) - Exercise/Conversion
Common Stock
2015-08-31$20.30/sh+10,000$203,000→ 18,200 total - Sale
Common Stock
2015-08-31$41.39/sh−10,000$413,900→ 8,200 total - Exercise/Conversion
Stock Option (Right to Buy)
2015-08-31−10,000→ 0 totalExercise: $20.30Exp: 2020-05-26→ Common Stock (10,000 underlying)
Footnotes (5)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold at prices ranging from $42.29 to $42.71 in multiple transactions. The reporting person undertakes to provide to Impax Laboratories, Inc., any security holder of Impax Laboratories, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold at prices ranging from $40.39 to $42.75 in multiple transactions. The reporting person undertakes to provide to Impax Laboratories, Inc., any security holder of Impax Laboratories, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold at prices ranging from $40.39 to $42.75 in multiple transactions. The reporting person undertakes to provide to Impax Laboratories, Inc., any security holder of Impax Laboratories, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
- [F4]Of the 12,000 shares underlying the options, 8,000 of the shares subject to the option are fully vested and exercisable.
- [F5]100% of the shares subject to the option are fully vested and exercisable.